Testing antiviral compounds in a dengue mouse model.

Methods Mol Biol

Department of Infectious Diseases, Novartis Institutes for Biomedical Research, Emeryville, CA, USA.

Published: January 2014

Dengue fever is an emerging mosquito-borne flaviviral disease that threatens 2.5 billion people worldwide. No clinically approved vaccine and antiviral therapy are currently available to prevent or treat dengue virus (DENV) infection. Vertebrate animals other than primates are not normally infectable with DENV; however, a small animal dengue infection model would greatly facilitate the development of a vaccine or an antiviral therapy. To this end, a rodent model for DENV infection has been established in IFN-α/β and IFN-γ receptor-deficient (AG129) mice. This chapter describes the protocol for the DENV infection model in AG129 mice and testing of antiviral compounds by oral gavage or parenteral injection.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-484-5_21DOI Listing

Publication Analysis

Top Keywords

denv infection
12
testing antiviral
8
antiviral compounds
8
vaccine antiviral
8
antiviral therapy
8
infection model
8
ag129 mice
8
dengue
4
compounds dengue
4
dengue mouse
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!